Kanał BNR
BN

Burning Rock Biotech Limited

BNR · NASDAQ

$12.80 +10.70% (+$1.24)
1M +34.48%
Market Cap ¥90.6M
P/E Ratio -
Div. Yield -
ROE 12.97%
Piotroski F-Score Weak
3/9
Valuation
100 /100
Cheap
P/B 0.18x
P/S 0.18x
EV/FFO N/A
Growth
10 /100
Declining
Book val. growth 22.67%
Rev. growth 1.42%
FCF growth N/A
Profitability
20 /100
Weak
Net margin 13.59%
Op. margin 12.99%
FCF margin 7.88%
Quality
8 /100
Poor
ROE 12.97%
ROA 9.06%
Asset turnover 0.67x
Debt
69 /100
Low
Current ratio 3.03x
Int. coverage -1,104.23x
Debt/Equity 0.09x
Stability
53 /100
Moderate
Rev. volatility 5.15%
EPS volatility 50.71%
Profitable years 0

Bulios Scoring opisuje jakość i historię firmy, a nie przyszły zwrot. Wysoki wynik to nie sygnał zakupu. Dowiedz się więcej

Zapytaj StockBota o BNR
Online

O spółce

Burning Rock Biotech Limited (BNR) is a biotechnology company focused on the development and commercialization of diagnostic tests for oncological diseases. Their products include genetic tests and tests for the detection of tumor biomarkers, which help physicians accurately diagnose and treat cancer. Burning Rock Biotech is known for its ability to integrate advanced technologies such as DNA sequencing and artificial intelligence into its diagnostic tests, enabling rapid and precise diagnosis of cancerous diseases. The company also focuses on developing personalized treatment approaches that improve treatment outcomes for cancer patients. Burning Rock Biotech Limited (BNR) shares could be suitable for investors looking for opportunities in the biotechnology sector with an emphasis on cancer diagnosis and treatment.

Opis nie jest jeszcze dostępny w Twoim języku, więc tekst jest po angielsku.

Sector

Healthcare

Industry

Medical - Diagnostics & Research

CEO

Yusheng Han

Employees

667

Headquarters

Guangzhou

Nadchodzące wydarzenia

17 LIS

Earnings

Upcoming earnings report

61d

Używamy niezbędnych plików cookie do działania strony oraz opcjonalnych analitycznych plików cookie do pomiaru ruchu. Zobacz naszą Politykę prywatności.